Implementing a Methadone Delivery System in New York City in Response to COVID-19.
Where this comes from
- Record sourced from PubMed, PMID 34878865.
- Also identified by DOI 10.2105/AJPH.2021.306523 and PMC identifier 8667852.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Opioid agonist medication, including methadone, is considered the first-line treatment for opioid use disorder. Methadone, when taken daily, reduces the risk of fatal overdose; however, overdose risk increases following medication cessation. Amid an overdose epidemic accelerated by the proliferation of fentanyl, ensuring continuity of methadone treatment during the COVID-19 pandemic is a vital public health priority. (<i>Am J Public Health</i>. 2021;111(12):2115-2117. https://doi.org/10.2105/AJPH.2021.306523).
Medical subject headings
- COVID-19
- Communicable Disease Control
- Methadone
- Opiate Substitution Treatment
- Opioid-Related Disorders